Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shuhe granules (舒合颗粒) is a Traditional Chinese Medicine (TCM) hospital preparation developed by the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine). It is specifically formulated to treat rheumatoid arthritis (RA), particularly when accompanied by symptoms of insomnia, anxiety, or depression, which are categorized under the TCM syndrome of Liver-Qi stagnation and Spleen deficiency. The formula typically includes herbs such as *Paeonia lactiflora* (Bai Shao), *Glycyrrhiza uralensis* (Gan Cao), and *Ziziphus jujuba var. spinosa* (Suan Zao Ren). Its therapeutic mechanism involves the downregulation of pro-inflammatory cytokines (such as TNF and IL-6) to reduce joint inflammation and the modulation of the GABAergic system to improve sleep quality and emotional stability. As a hospital preparation, its use is primarily localized to the developing institution's clinical practice and is regulated under China's hospital-specific drug preparation standards.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shuhe granules.